No clear answer
Memantine: slow disability worsening in MS (type not specified)
MS (type not specified) · Axonal protection / ion channels / excitotoxicity
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 20
How the verdict was reached
No result yet
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Memantine-MS | Phase 2 | 20 | 2007 | Stopped Paper abstract | Stopped before a result |
Counted: 0. Will count later: 0. Not counted: 1.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as No clear answer
Related hypotheses
- Amiloride: protect nerve tissue in MS (type not specified)
- Epoetin alfa: protect nerve tissue in MS (type not specified)
- Oxcarbazepine: protect nerve tissue in MS (type not specified)
- Phenytoin: protect nerve tissue in MS (type not specified)
- Gabapentin: repair myelin in MS (type not specified)
- Dronabinol: slow disability worsening in MS (type not specified)
- Levetiracetam: slow disability worsening in MS (type not specified)
- Pregabalin: slow disability worsening in MS (type not specified)
Assembled by software from public sources.